Genes and variant counts for pathways significantly associated with familial lymphoid cancer cases. by Sneha Ralli (16016296)

Multivariable logistic analysis showing significant indicators and their odds ratios of dengue confirmation in the health facility-based fever surveillance. by Jacqueline Kyungah Lim (10125351)

Characterization and outcomes of lymphoma cases based on stage (T-zone cases not included). by Heather Wilson-Robles (731578)

Indicators for competitive comparative advantage and their significance. by Linhan Shao (20978182)

Subjects:

Screening Sheet: A sheet that contains the full screening process that we used to include or exclude any study. by Mohamed R. Abdelraouf (21501468)

Cases based on number of DG allocation units. by Zeeshan Memon Anjum (12413383)

Subjects:

Deterministic result of the base-case analysis. by Sudewi Mukaromah Khoirunnisa (15288505)

“…Efficacy data and baseline characteristics in the base-case analysis were primarily derived from the 11-year results of the HERA trial. …”

Base-case estimated number of patients categorised in different phenotypes and age groups and their base-case cost of management. by Siew Chin Ong (9314213)

Base-case results based on evidence from randomized controlled trials (means and ranges). The comparator is no intervention. by Afschin Gandjour (342184)

Base-case results (deterministic analysis). by Robert Hodgson (2026294)

Base-case results: Probabilistic analysis. by Robert Hodgson (2026294)

Significantly Enriched Pathways. by Jiyong Zhang (2498740)

“…By comparing samples from NAFLD patients and healthy controls, we identified 1,770 significant DEGs, with 1,073 being upregulated and 697 downregulated. …”

Base-case results. by Mingxi Xie (19812594)

“…Clinical findings have showed that deprescribing service significantly decreased inappropriate PPIs utilization. …”

Base-case results. by Ping Chen (89712)

The base case analysis. by Wenwang Lang (20293527)

“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”

Top contributor of tissues of significant genes for AD. By ranking tissues based on their loadings in matrix <i>T</i>, we identified which tissues are the top contributors to signi... by Yan Yan (208529)

Base-case results. by Shuo Kang (1306860)

“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”

Multivariable logistic analysis showing significant indicators and their odds ratios of dengue positivity in the health facility-based fever surveillance. by Jacqueline Kyungah Lim (10125351)

Base-case analysis. by Akiko Kowada (14659965)

“…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …”

Characterization and outcomes of lymphoma cases based on immunophenotype. by Heather Wilson-Robles (731578)